Chetty Terusha, Thorne Claire, Tanser Frank, Bärnighausen Till, Coutsoudis Anna
Wellcome Trust Africa Health Research Institute, KwaZulu-Natal, South Africa.
Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, KwaZulu-Natal, South Africa.
BMJ Open. 2016 Oct 17;6(10):e012088. doi: 10.1136/bmjopen-2016-012088.
The Hlabisa pregnancy cohort was established to evaluate the effectiveness of prevention of mother-to-child transmission (PMTCT) guideline revisions. The objectives of the Hlabisa pregnancy cohort are to: (1) provide cohort-level information on maternal health up to 6 weeks postpartum in a high HIV prevalence setting; and to (2) evaluate aspects of PMTCT care that have policy relevance.
The pregnancy cohort is located in primary health clinics in the Hlabisa subdistrict of rural KwaZulu-Natal, South Africa. Baseline data collection between 2010 and 2014 has been completed with the enrolment of 25 608 pregnancies; age ranged from 15-49 years. Pregnant women were assessed during routine antenatal visits: first visit, follow-up 1 week later, 32 weeks (HIV test), infant delivery and 6 weeks postpartum. Demographic, pregnancy, clinical, laboratory and HIV data were collected through Department of Health interviews, laboratory tests and routine data linkage. Treatment data for HIV-infected pregnant women were linked to the Africa Centre Hlabisa HIV Treatment and Care Programme for detailed antiretroviral therapy (ART) history and laboratory tests.
The proportion of women initiated on ART post-2013 were higher (n=437; 100%) than pre-2013 (n=768; 84.2%). The proportion of women in care at 6 weeks (73.8%) was also higher post-2013 relative to earlier years (58.5%). The majority of HIV-infected pregnant women were either on lifelong ART or ART prophylaxis; pre-2013, ∼ 9.6% of women were not on any ART. Pregnancy viral load monitoring was inadequate.
This cohort will be used to: (1) determine HIV acquisition risk during pregnancy and postpartum; (2) determine the effect of HIV and ART on birth outcomes; (3) examine the effect of pregnancy on virological response to ART; and (4) characterise the effect of sequential pregnancies on access to clinical care, response to prolonged ART and birth outcomes.
建立Hlabisa妊娠队列以评估预防母婴传播(PMTCT)指南修订的有效性。Hlabisa妊娠队列的目标是:(1)在艾滋病毒高流行环境中提供产后6周内产妇健康的队列水平信息;以及(2)评估具有政策相关性的PMTCT护理方面。
妊娠队列位于南非夸祖鲁 - 纳塔尔省农村Hlabisa分区的初级卫生诊所。2010年至2014年期间的基线数据收集工作已经完成,共有25608例妊娠登记入组;年龄范围为15 - 49岁。孕妇在常规产前检查期间接受评估:首次就诊、1周后随访、32周(艾滋病毒检测)、婴儿分娩和产后6周。通过卫生部访谈、实验室检测和常规数据链接收集人口统计学、妊娠、临床、实验室和艾滋病毒数据。感染艾滋病毒孕妇的治疗数据与非洲中心Hlabisa艾滋病毒治疗与护理项目相关联,以获取详细的抗逆转录病毒疗法(ART)病史和实验室检测结果。
2013年后开始接受ART治疗的女性比例(n = 437;100%)高于2013年前(n = 768;84.2%)。2013年后产后6周接受护理的女性比例(73.8%)也高于早年(58.5%)。大多数感染艾滋病毒的孕妇要么接受终身ART治疗,要么接受ART预防治疗;2013年前,约9.6%的女性未接受任何ART治疗。妊娠病毒载量监测不足。
该队列将用于:(1)确定妊娠和产后感染艾滋病毒的风险;(2)确定艾滋病毒和ART对出生结局的影响;(3)研究妊娠对ART病毒学反应的影响;以及(4)描述连续妊娠对获得临床护理、对长期ART治疗的反应和出生结局的影响。